TIDMCRV

RNS Number : 9418Q

Craven House Capital PLC

23 October 2023

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF REGULATION (EU) 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EU (WITHDRAWAL) ACT 2018.

Craven House Capital plc

("Craven House" or the "Company")

Investee company update: Bio Vitos

Further to the announcement of 3 July 2023 at 01:32pm Craven House announces that the transaction between its investee company, Bio Vitos, and Hemcheck Sweden AB ("Hemcheck") has received approval from Nasdaq Stockholm. Bio Vitos will now proceed to completion of the transaction which is anticipated during September, 2023. Upon completion Bio Vitos will own 259,654,000 shares in Hemcheck.. This amounts to 88.3% of Hemcheck's share capital.

Craven House's holding in Bio Vitos will remain unchanged.

The full text of the announcement released by Hemcheck today has been translated and set out below:

" PRESS RELEASE

Hemcheck has been conditionally approved for continued listing by Nasdaq and can complete the transaction with Bio Vitos

Hemcheck has been approved for continued listing by Nasdaq, subject to the transaction with Bio Vitos being carried out and other customary conditions such as updating the website after the transaction is completed.

With this, the company description that has been produced is published and this can also be found on the company's website, www.hemcheck.se. This also means that the transaction with Bio Vitos, where IP rights and capital are acquired, can be completed.

The company will quickly implement all the steps required to complete the transaction with Bio Vitos. Additional information will be shared as soon as final dates are determined.

For further information please contact:

 
Craven House Capital Plc         Tel: 0203 286 8130 
 Mark Pajak 
 www.Cravenhousecapital.com 
SI Capital                       Tel: 01483 413500 
 Broker 
 Nick Emerson 
 www.sicapital.co.uk 
 
  SPARK Advisory Partners          Tel: 0203 368 3550 
  Limited 
  Nominated Adviser 
  Matt Davis/James Keeshan 
  www.Sparkadvisorypartners.com

About Craven House Capital:

The Company's Investing Policy is primarily to invest in or acquire a portfolio of companies, partnerships, joint ventures, businesses or other assets participating in the e-Commerce sector.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

PFUEXLBLXBLXFBX

(END) Dow Jones Newswires

October 23, 2023 02:04 ET (06:04 GMT)

Craven House Capital (LSE:CRV)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Craven House Capital Charts.
Craven House Capital (LSE:CRV)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Craven House Capital Charts.